Patient reported outcomes from a Randomized Controlled Phase 3 Trial of Sarilumab in Polymyalgia Rheumatica

Sponsored by Sanofi

Mar 09, 2023 11:51 am

More Video Posters

Avacopan Poster

Safety of Avacopan in ANCA-Associated Vasculitis: Combined Data from Three Clinical Trials

Glucocorticoid Poster

Glucocorticoid (GC)-free resolution of polymyalgia rheumatica (PMR) signs and symptoms in patients treated with sarilumab with history of flare: analysis from SAPHYR

Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)

Bimekizumab Poster

Bimekizumab Maintains Improvements in Efficacy Endpoints and has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies

Presenter(s):

Vibeke Strand, Jennifer Sloane Lazar, Michael C Nivens, Jingdong Chao, Stefano Fiore, Angelika Giannelou, Lita Araujo, and Jerome Msihid

Abstract or description:

The poster reports the patient reported outcomes from the SAPHYR study. Patients treated with sarilumab 200mg Q2W + 14-week GC had clinically meaningful and robust improvement in patient reported outcomes compared to patients receiving placebo + 52-week GC.

×